Chemed Reports Second-Quarter 2018 Results - Earnings Guidance Increased
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Chemed (CHE) PT Raised to $340 at Oppenheimer
July 27, 2018 9:37 AM EDTOppenheimer raised its price target on Chemed (NYSE: CHE) to $340.00 (from $315.00) while maintaining a Outperform rating.
Analyst Michael Wiederhorn commented, "CHE reported 2Q:18 adj. EPS of $2.81 (GAAP: $3.27) vs. OPCO/Street ests. of $2.68/$2.77. Adj. results exclude the normal items (OIG/stock... More
